Global multi-stakeholder endorsement of the MAFLD definition

TY - JOUR

T1 - Global multi-stakeholder endorsement of the MAFLD definition

AU - Global multi-stakeholder consensus on the redefinition of fatty liver disease

AU - Méndez-Sánchez, Nahum

AU - Bugianesi, Elisabetta

AU - Gish, Robert G.

AU - Lammert, Frank

AU - Tilg, Herbert

AU - Nguyen, Mindie H.

AU - Sarin, Shiv K.

AU - Fabrellas, Núria

AU - Zelber-Sagi, Shira

AU - Fan, Jian Gao

AU - Shiha, Gamal

AU - Targher, Giovanni

AU - Zheng, Ming Hua

AU - Chan, Wah Kheong

AU - Vinker, Shlomo

AU - Kawaguchi, Takumi

AU - Castera, Laurent

AU - Yilmaz, Yusuf

AU - Korenjak, Marko

AU - Spearman, C. Wendy

AU - Ungan, Mehmet

AU - Palmer, Melissa

AU - El-Shabrawi, Mortada

AU - Gruss, Hans Juergen

AU - Dufour, Jean François

AU - Dhawan, Anil

AU - Wedemeyer, Heiner

AU - George, Jacob

AU - Valenti, Luca

AU - Fouad, Yasser

AU - Romero‐Gomez, Manuel

AU - Eslam, Mohammed

AU - Abate, Maria Lorena

AU - Abbas, Bahaa

AU - Abbassy, Ahmed Amr

AU - Abd El Ghany, Waleed

AU - Abd Elkhalek, Amira

AU - Abd ElMajeed, Emad

AU - Abdalgaber, Mohammad

AU - AbdAllah, Mohamed

AU - Abdallah, Marwa

AU - Abdallah, Nourhan

AU - Abdelaleem, Shereen

AU - Abdelghani, Yasser

AU - Abdelghany, Wael

AU - Abdelhalim, Safaa Mohamed

AU - Abdelhamid, Wafaa

AU - Abdelhamid, Nehal

AU - Abdelkader, Nadia A.

AU - Al-Busafi, Said

N1 - Funding Information: HW reports personal fees from Falk Foundation, Gore, Intercept, Pfizer, Merz, and Norgine; and grants from Merz and from Norgine, unrelated to this Correspondence. W-KC reports personal fees from Abbvie, Novo Nordisk, Boehringer Ingelheim, Viatris, and Hisky Medical, unrelated to this Correspondence. TK reports honorarium for lectures from Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical, and EA Pharma, unrelated to this Correspondence. LC reports personal fees from Alexion, AbbVie, Echosens, Gilead, Intercept, Merck, Novo Nordisk, and Pfizer; and grants from Gilead, unrelated to this Correspondence. MHN reports grants from Glycotest, Gilead, Pfizer, Enanta, BK Kee Foundation, National Cancer Institute, and Vir Biotech; and personal fees from Spring Bank, Novartis, Janssen Eisai, Bayer, Intercept, Exact Science, Laboratory of Advanced Medicine, Helio, and Eli Lilly. MHN also reports acting as a consultant or on an advisory board for Gilead, unrelated to this Correspondence. LV reports grants from Gilead and personal fees from Viatris, unrelated to this Correspondence. RGG has received grants or research support in past 2 years from Gilead. RGG has also performed as a consultant or advisor in the past 2 years to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, and Venatorx. RGG is on scientific or clinical advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, and Prodigy. RGG has performed as a consultant, advisor, or both to Topography Health. RGG is chair of the clinical advisory board for Prodigy. RGG is an advisory consultant for Fibronostics, Fujifilm–Wako, Perspectum, Quest, and Sonic Incytes. RGG is on data safety monitoring boards for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect. RGG currently has consulting confidentiality agreements with AbbVie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals, ArrowHead, Arterys, Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Association, CymaBay Therapeutics, DiaSorin, Dova Pharmaceuticals, DRG Abacus, Durect, Dynavax, Echosens, Eiger, Enyp, Exelixis, Fibronostics, Forty-Seven, Fujifilm Wako Diagnostics, Gilead Sciences, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen–Johnson & Johnson, KannaLife, Laboratory for Advanced Medicine, Labyrinth, Life Line Screening, Eli Lilly, MedImmne, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, Prodigy Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi, Spring Bank, and Trimaran. RGG has speaker's contracts to do promotional talks for AbbVie, Bristol Myers Squibb, Eisai, Gilead Sciences, and Intercept. RGG is a minor stock shareholder (only for projects in the liver field but not fatty liver disease-related areas) for RiboSciences and CoCrystal. RGG holds stock options in Eiger, Genlantis, HepQuant, and AngioCrine, unrelated to this Correspondence. All other authors declare no competing interests.

PY - 2022/5

Y1 - 2022/5

KW - Humans

KW - Non-alcoholic Fatty Liver Disease

UR - http://www.scopus.com/inward/record.url?scp=85127533180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127533180&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(22)00062-0

DO - 10.1016/S2468-1253(22)00062-0

M3 - Letter

C2 - 35248211

AN - SCOPUS:85127533180

SN - 2468-1253

VL - 7

SP - 388

EP - 390

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 5

ER -